# Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

> **NCT03636659** · PHASE1 · COMPLETED · sponsor: **Aurobindo Pharma Ltd** · enrollment: 140 (actual)

## Conditions studied

- Visceral Leishmaniasis

## Interventions

- **DRUG:** Amphotericin B Liposome
- **DRUG:** AmBisome (Amphotericin B) Liposome

## Key facts

- **NCT ID:** NCT03636659
- **Lead sponsor:** Aurobindo Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2019-04-05
- **Final completion:** 2019-04-05
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2019-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636659, "Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03636659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*